Renal Effect of Pentoxyphylline in High Risk Patients Undergoing Angiography
Contrast Induced Nephropathy, Diabetes Mellitus
About this trial
This is an interventional prevention trial for Contrast Induced Nephropathy focused on measuring diabetes mellitus, creatinin level, contrast induced nephropathy, prevention contrast induced nephropathy in high risk patients
Eligibility Criteria
Inclusion Criteria:
Cardiology patients:
- Hospitalization for ACS (acute coronary syndrome) with NSTEMI or Unstable Angina
- Diabetic patients (treated with insulin or oral hypoglycemic drugs) or patients with basal serum creatinine greater than 1.3mg/dl in females and 1.5 mg/dl in male patients.
- Informed consent
- Age between 18-75
Radiology patients:
- Radiology patients should be diabetic patients (treated with insulin or oral hypoglycemic drugs) or patients with basal serum creatinine of 1.3mg/dl in females and 1.5 mg/dl in male patients.
- Informed consent
- Age between 18-75
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Placebo Comparator
Experimental
Placebo Comparator
pentoxyphylline cardio
placebo cardio
radiology pentoxyphylline
radiology placebo
Patients with chronic renal failure (CRF) and/or diabetes mellitus (DM) who are about to go to undergo coronary angiography
Patients with chronic renal failure (CRF) and/or diabetes mellitus (DM) who are about to go to undergo coronary angiography
Patients with chronic renal failure (CRF) and/or diabetes mellitus (DM) who are about to go to undergo computed tomography with contrast
Patients with chronic renal failure (CRF) and/or diabetes mellitus (DM) who are about to go to undergo computed tomography with contrast